In vitro effect of a new cinnamic acid derivative against the epimastigote form of Trypanosoma cruzi
An intensive effort has been directed toward finding alternative drugs for treatment of Chagas' disease, caused by Trypanosoma cruzi (T. cruzi), and prophylaxis of blood in endemic areas. The preparation and in vitro evaluation as potential anti-protozoal agent of (2E)-N-(1,3-benzothiazol-2-yl)...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2009
|
| Materias: | |
| Acceso en línea: | Registro en Scopus Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 08320caa a22010097a 4500 | ||
|---|---|---|---|
| 001 | PAPER-8729 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518203833.0 | ||
| 008 | 190411s2009 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-66149168381 | |
| 024 | 7 | |2 cas |a (2E)-N-(1,3-benzothiazol-2-yl)-3-(2,5-dimethoxyphenyl)-2-propenamide; Amides; Annexin A5; Benzothiazoles; Cinnamates; Coloring Agents; Enzyme Inhibitors; Indicators and Reagents; Propidium, 36015-30-2; Reactive Oxygen Species; Trypanocidal Agents; cinnamic acid, 621-82-9 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a ARZNA | ||
| 100 | 1 | |a Andreu, G.L.P. | |
| 245 | 1 | 3 | |a In vitro effect of a new cinnamic acid derivative against the epimastigote form of Trypanosoma cruzi |
| 260 | |c 2009 | ||
| 270 | 1 | 0 | |m Andreu, G. L. P.; Centro de Estudios para Las Investigaciones Y Evaluaciones Biólogicas, Instituto de Farmacia Y Alimentos, Universidad de La Habana, Ave. 23 # 21425e/214 y 222, La Coronela, La Lisa, Ciudad Habana, Cuba; email: gilbertopardo@infomed.sld.cu |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Vinhaes, M.C., Schofield, C.J., Trypanosomiasis control: Surmounting diminishing returns (2003) Trends Parasitol, 19, pp. 112-113 | ||
| 504 | |a Coura, J.R., De Castro, S.L., A critical review on chagas disease chemotherapy (2002) Memorias Do Instituto Oswaldo Cruz, 97 (1), pp. 3-24 | ||
| 504 | |a Castro, J.A., De Mecca, M.M., Bartel, L.C., Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis) (2006) Human and Experimental Toxicology, 25 (8), pp. 471-479. , DOI 10.1191/0960327106het653oa | ||
| 504 | |a Halestrap, A.P., The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors (1975) Biochem J, 148, pp. 85-96 | ||
| 504 | |a Halestrap, A.P., Transport of pyruvate and lactate into human erythrocytes: Evidence for the involvement of the chloride carrier and a chloride-independent carrier (1976) Biochem J, 156, pp. 193-207 | ||
| 504 | |a Pellón, R.F., Mamposo, T., González, E., Calderón, O., Synthesis of cinnamic acid derivatives using ethanol as solvent or microwave assisted method (2000) Synth Commun, 30, pp. 3769-3774 | ||
| 504 | |a Denicola-Seoane, A., Rubbo, H., Prodanov, E., Turrens, J., Succinate- Dependent metabolism in Trypanosoma cruzi epimastigotes (1992) Mol Biochem Parasit, 54, pp. 43-50 | ||
| 504 | |a Gornall, A.G., Bardawill, C.J., David, M.M., Determination of serum proteins by means of biuret reaction (1949) J Biol Chem, 177, pp. 751-766 | ||
| 504 | |a Gomes, A., Fernandes, E., Lima, J.L.F.C., Fluorescence probes used for detection of reactive oxygen species (2005) Journal of Biochemical and Biophysical Methods, 65 (2-3), pp. 45-80. , DOI 10.1016/j.jbbm.2005.10.003, PII S0165022X05001454 | ||
| 504 | |a Rottenberg, H., Shaolong, W., Quantitative assay by flow cytometry of the mitochondrial membrane potential in intact cells (1998) Biochimica et Biophysica Acta - Molecular Cell Research, 1404 (3), pp. 393-404. , DOI 10.1016/S0167-4889(98)00088-3, PII S0167488998000883 | ||
| 504 | |a Buckner, F., Yokoyama, K., Lockman, J., Aikenhead, K., Ohkanda, J., Sadilek, M., Sebti, S., Gelb, M.H., A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents (2003) Proceedings of the National Academy of Sciences of the United States of America, 100 (25), pp. 15149-15153. , DOI 10.1073/pnas.2535442100 | ||
| 504 | |a Menna-Barreto, R.F.S., Henriques-Pons, A., Pinto, A.V., Morgado-Diaz, J.A., Soares, M.J., De Castro, S.L., Effect of a b-lapachone-derived naphthoimidazole on Trypanosoma cruzi: Identification of target organelles (2005) Journal of Antimicrobial Chemotherapy, 56 (6), pp. 1034-1041. , DOI 10.1093/jac/dki403 | ||
| 504 | |a Piacenza, L., Irigoin, F., Alvarez, M.N., Peluffo, G., Taylor, M.C., Kelly, J.M., Wilkinson, S.R., Radi, R., Mitochondrial superoxide radicals mediate programmed cell death in Trypanosoma cruzi: Cytoprotective action of mitochondrial iron superoxide dismutase overexpression (2007) Biochemical Journal, 403 (2), pp. 323-334. , DOI 10.1042/BJ20061281 | ||
| 504 | |a Viswalingam, A., Caldwell, J., Cinnamyl anthranilate causes coinduction of hepatic microsomal and peroxisomal enzymes in mouse but not rat (1997) Toxicology and Applied Pharmacology, 142 (2), pp. 338-347. , DOI 10.1006/taap.1996.8043 | ||
| 520 | 3 | |a An intensive effort has been directed toward finding alternative drugs for treatment of Chagas' disease, caused by Trypanosoma cruzi (T. cruzi), and prophylaxis of blood in endemic areas. The preparation and in vitro evaluation as potential anti-protozoal agent of (2E)-N-(1,3-benzothiazol-2-yl)-3-(2,5- dimethoxyphenyl)-2-propenamide (CAD-1) is presented. The results show that 0.05 mMCAD-1 induced 58.1% of T. cruzi epimastigotes death; mainly by apoptosis. The diminution in the transmembrane mitochondrial electrical potential together with the increase in the intracellular generation/accumulation of reactive oxygen species, suggest the parasites mitochondria as the main target for CAD-1-induced death. The concentration of 0.05 mM CAD-1 is not low enough to consider it as a potent tripanocydal agent. However the novel mechanismthat induce s T. cruzi death, together with the novelty of its chemical structure, point out CAD-1 as a head group compound that could serve as a template to obtain new, more potent anti-Chagas disease agents. © ECV Editio Cantor Verlag. |l eng | |
| 593 | |a Departamento de Investigaciones Biomédicas, Centro de Química Farmacéutica, Ciudad de La Habana, Cuba | ||
| 593 | |a Centro de Estudios para Las Investigaciones Y Evaluaciones Biólogicas, Instituto de Farmacia Y Alimentos, Universidad de La Habana, Ciudad Habana, Cuba | ||
| 593 | |a Departamento de Patologia Clínica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, Brazil | ||
| 593 | |a Departamento de Química Orgánica, Facultad de Ciencias Exactas Y Naturales, Ciudad Universitaria, Buenos Aires, Argentina | ||
| 593 | |a Centro de Estudios para Las Investigaciones Y Evaluaciones Biólogicas, Instituto de Farmacia Y Alimentos, Universidad de La Habana, Ave. 23 # 21425e/214 y 222, La Coronela, La Lisa, Ciudad Habana, Cuba | ||
| 690 | 1 | 0 | |a ANTI-PROTOZOAL AGENTS |
| 690 | 1 | 0 | |a CHAGAS' DISEASE |
| 690 | 1 | 0 | |a CINNAMIC ACID |
| 690 | 1 | 0 | |a EPIMASTIGOTES |
| 690 | 1 | 0 | |a MITOCHONDRIA |
| 690 | 1 | 0 | |a OXIDATIVE STRESS |
| 690 | 1 | 0 | |a TRYPANOSOMA CRUZI |
| 690 | 1 | 0 | |a CAD 1 |
| 690 | 1 | 0 | |a CINNAMIC ACID DERIVATIVE |
| 690 | 1 | 0 | |a N (1,3 BENZOTHIAZOL 2 YL) 3 (2,5 DIMETHOXYPHENYL) 2 PROPENAMIDE |
| 690 | 1 | 0 | |a REACTIVE OXYGEN METABOLITE |
| 690 | 1 | 0 | |a UNCLASSIFIED DRUG |
| 690 | 1 | 0 | |a ANTIPROTOZOAL ACTIVITY |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a DRUG MECHANISM |
| 690 | 1 | 0 | |a DRUG STRUCTURE |
| 690 | 1 | 0 | |a EPIMASTIGOTE |
| 690 | 1 | 0 | |a IN VITRO STUDY |
| 690 | 1 | 0 | |a MITOCHONDRIAL MEMBRANE POTENTIAL |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a TRYPANOSOMA CRUZI |
| 690 | 1 | 0 | |a AMIDES |
| 690 | 1 | 0 | |a ANIMALS |
| 690 | 1 | 0 | |a ANNEXIN A5 |
| 690 | 1 | 0 | |a BENZOTHIAZOLES |
| 690 | 1 | 0 | |a CINNAMATES |
| 690 | 1 | 0 | |a COLORING AGENTS |
| 690 | 1 | 0 | |a ENZYME INHIBITORS |
| 690 | 1 | 0 | |a FLOW CYTOMETRY |
| 690 | 1 | 0 | |a INDICATORS AND REAGENTS |
| 690 | 1 | 0 | |a MEMBRANE POTENTIALS |
| 690 | 1 | 0 | |a PROPIDIUM |
| 690 | 1 | 0 | |a REACTIVE OXYGEN SPECIES |
| 690 | 1 | 0 | |a TRYPANOCIDAL AGENTS |
| 690 | 1 | 0 | |a TRYPANOSOMA CRUZI |
| 653 | 0 | 0 | |a cad 1 |
| 700 | 1 | |a Inada, N.M. | |
| 700 | 1 | |a Pellón, R.F. | |
| 700 | 1 | |a Docampo, M.L. | |
| 700 | 1 | |a Fascio, M.L. | |
| 700 | 1 | |a D'Accorso, N.B. | |
| 700 | 1 | |a Vercesi, A.E. | |
| 773 | 0 | |d 2009 |g v. 59 |h pp. 207-211 |k n. 4 |p Arzneim.-Forsch. Drug Res. |x 00044172 |t Arzneimittel-Forschung/Drug Research | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-66149168381&partnerID=40&md5=1e067978723c6cb334e95f53cf824961 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_00044172_v59_n4_p207_Andreu |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00044172_v59_n4_p207_Andreu |y Registro en la Biblioteca Digital |
| 961 | |a paper_00044172_v59_n4_p207_Andreu |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 69682 | ||